SUMO1 and leukemia: The results showed that although varying in abundance, SUMO1-conjugated K270-containing peptide of PKM2 was observed across a number of leukemia cell lines (Fig. 2D) and BMMC from leukemia patients (Fig. 2E), clearly demonstrating that endogenous SUMOylation of PKM2 is prevalent in leukemia cells.